Ocuphire Pharma Results
APX3330 is Positioned to Fulfill a Significant Unmet Need in Diabetic Eye Disease
Ocuphire
PHARMA
Favorable PK and safety
data from clinical trials
and overall masked safety
data supports a potential
oral treatment for
diabetics with DR/DME
Ý
Dual mechanism of action
may benefit inflammation
from co-morbidities
Oral therapeutic decreases burden of
treatment (invasive intravitreal injections,
time devoted to treatment, etc.) which
may strengthen adherence and overall
favorable outcomes
mis
DR/DME treatments
are large attractive
market opportunity
Oral therapeutic can be prescribed as
early treatment option for diabetic
patients who may otherwise fall under
the "wait and see" treatment approach
Well-controlled, multi-center Phase 2b ZETA-1 for APX3330 topline results expected in 4Q22
53View entire presentation